Sort by
Previous Page Page 1 of 299 Next Page
  1. Research article

    Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma - in vitro and in vivo

    Former studies already revealed the anti-neoplastic properties of the anti-infective agent Taurolidine (TRD) against many tumor species in vitro and in vivo. Its anti-proliferative and cell death inducing capacit...

    M. Buchholz, B. Majchrzak-Stiller, S. Hahn, D. Vangala, R. W. Pfirrmann, W. Uhl, C. Braumann and A. M. Chromik

    BMC Cancer 2017 17:216

    Published on: 24 March 2017

  2. Research article

    u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression

    Multiple Myeloma (MM) is a B-cell malignancy in which clonal plasma cells progressively expand within the bone marrow (BM) as effect of complex interactions with extracellular matrix and a number of microenvir...

    S Ciavarella, A Laurenzana, S De Summa, B Pilato, A Chillà, R Lacalamita, C Minoia, F Margheri, A Iacobazzi, A Rana, F Merchionne, G Fibbi, M Del Rosso, A Guarini, S Tommasi and S Serratì

    BMC Cancer 2017 17:215

    Published on: 24 March 2017

  3. Research article

    Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy

    We designed a single-arm, open-label phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy (#NCT02449538).

    Seung Tae Kim, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Won Ki Kang and Ho Yeong Lim

    BMC Cancer 2017 17:211

    Published on: 23 March 2017

  4. Research article

    Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin

    We evaluated possible diagnostic and prognostic values of serum midkine in malignant pleural mesothelioma in comparison with those of serum mesothelin, a well-established diagnostic biomarker.

    Guntulu Ak, Yuji Tada, Hideaki Shimada, Selma Metintas, Masaaki Ito, Kenzo Hiroshima, Masatoshi Tagawa and Muzaffer Metintas

    BMC Cancer 2017 17:212

    Published on: 23 March 2017

  5. Research article

    Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging

    Accurate measurement of tumor burden in breast cancer disease is essential to improve the clinical management of patients. In this study, we evaluate whether the fluctuations in the fraction of PIK3CA mutant a...

    José Angel García-Saenz, Patricia Ayllón, Marion Laig, Daniel Acosta-Eyzaguirre, Marta García-Esquinas, Myriam Montes, Julián Sanz, Miguel Barquín, Fernando Moreno, Vanesa Garcia-Barberan, Eduardo Díaz-Rubio, Trinidad Caldes and Atocha Romero

    BMC Cancer 2017 17:210

    Published on: 22 March 2017

  6. Study protocol

    Uniform FDG-PET guided GRAdient Dose prEscription to reduce late Radiation Toxicity (UPGRADE-RT): study protocol for a randomized clinical trial with dose reduction to the elective neck in head and neck squamous cell carcinoma

    In definitive radiation therapy for head and neck cancer, clinically uninvolved cervical lymph nodes are irradiated with a so-called ‘elective dose’ in order to achieve control of clinically occult metastases....

    Sven van den Bosch, Tim Dijkema, Martina C. Kunze-Busch, Chris H. J. Terhaard, Cornelis P. J. Raaijmakers, Patricia A. H. Doornaert, Frank J. P. Hoebers, Marije R. Vergeer, Bas Kreike, Oda B. Wijers, Wim J. G. Oyen and Johannes H. A. M. Kaanders

    BMC Cancer 2017 17:208

    Published on: 21 March 2017

  7. Research article

    Simultaneous analysis of miRNA-mRNA in human meningiomas by integrating transcriptome: A relationship between PTX3 and miR-29c

    Although meningioma is a common disease, there is a lack of understanding of the underlying molecular mechanisms behind its initiation and progression. We used combined miRNA-mRNA transcriptome analysis to dis...

    Altay Burak Dalan, Sukru Gulluoglu, Emre Can Tuysuz, Aysegul Kuskucu, Cumhur Kaan Yaltirik, Oguz Ozturk, Ugur Ture and Omer Faruk Bayrak

    BMC Cancer 2017 17:207

    Published on: 21 March 2017

  8. Research article

    The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures

    Glioblastoma multiforme (GBM) is the most common, invasive and deadly primary type of malignant brain tumor. The Phosphatidylinositol-3-Kinase/AKT (PI3K/AKT) pathway is highly active in GBM and has been associ...

    Ravi S. Narayan, Carlos A. Fedrigo, Eelke Brands, Rogier Dik, Lukas J.A. Stalpers, Brigitta G. Baumert, Ben J. Slotman, Bart A. Westerman, Godefridus J. Peters and Peter Sminia

    BMC Cancer 2017 17:204

    Published on: 21 March 2017

  9. Research article

    Morphological and phenotypical features of ovarian metastases in breast cancer patients

    Autotransplantation of frozen-thawed ovarian tissue is a method to preserve ovarian function and fertility in patients undergoing gonadotoxic therapy. In oncology patients, the safety cannot yet be guaranteed,...

    Inge T. A. Peters, Merle A. van der Steen, Bertine W. Huisman, Carina G. J .M. Hilders, Vincent T. H. B. M. Smit, Alexander L. Vahrmeijer, Cornelis F. M. Sier, J. Baptist Trimbos and Peter J. K. Kuppen

    BMC Cancer 2017 17:206

    Published on: 21 March 2017

  10. Erratum

    Erratum to: Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients

    Rumyana Ivanova Dodova, Atanaska Velichkova Mitkova, Daniela Rosenova Dacheva, Lina Basam Hadjo, Alexandrina Ivanova Vlahova, Margarita Stoyanova Taushanova – Hadjieva, Spartak Stoyanov Valev, Marija Mitko Caulevska, Stanislava Dimitrova Popova, Ivan Emilov Popov, Tihomir Iliichev Dikov, Theophil Angelov Sedloev, Atanas Stefanov Ionkov, Konstanta Velinova Timcheva, Svetlana Liubomirova Christova, Ivo Marinov Kremensky…

    BMC Cancer 2017 17:195

    Published on: 16 March 2017

    The original article was published in BMC Cancer 2015 15:523

  11. Case report

    Objective response to mTOR inhibition in a metastatic collision tumor of the liver composed of melanoma and adenocarcinoma with TSC1 loss: a case report

    Collision tumors are uncommon but well described clinical entities composed of distinct tumor histologies occurring within the same anatomic site. Optimal management of patients with collision tumors remains h...

    Munveer S. Bhangoo, Jenny Y. Zhou, Siraj M. Ali, Russell Madison, Alexa B. Schrock and Carrie Costantini

    BMC Cancer 2017 17:197

    Published on: 16 March 2017

  12. Research article

    Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States

    Median age at diagnosis of patients with chronic lymphocytic leukemia (CLL) is > 70 years. However, the majority of clinical trials do not reflect the demographics of CLL patients treated in the community. We ...

    Chadi Nabhan, Anthony Mato, Christopher R. Flowers, David L. Grinblatt, Nicole Lamanna, Mark A. Weiss, Matthew S. Davids, Arlene S. Swern, Shriya Bhushan, Kristen Sullivan, E. Dawn Flick, Pavel Kiselev and Jeff P. Sharman

    BMC Cancer 2017 17:198

    Published on: 16 March 2017

  13. Research article

    Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells

    Approximately 18–20% of all human breast cancers have overexpressed human epidermal growth factor receptor 2 (HER2). Standard clinical practice is to treat only overexpressed HER2 (HER2+) cancers with targeted...

    Yao Huang, David J. Burns, Benjamin E. Rich, Ian A. MacNeil, Abhijit Dandapat, Sajjad M. Soltani, Samantha Myhre, Brian F. Sullivan, Carol A. Lange, Leo T. Furcht and Lance G. Laing

    BMC Cancer 2017 17:199

    Published on: 16 March 2017

  14. Research article

    YBX1 gene silencing inhibits migratory and invasive potential via CORO1C in breast cancer in vitro

    Y-box binding protein-1 is an evolutionary conserved transcription and translation regulating protein that is overexpressed in various human malignancies, including breast cancer. Despite reports of YB-1 and i...

    Jia Pei Lim, Sukanya Shyamasundar, Jayantha Gunaratne, Olivia Jane Scully, Ken Matsumoto and Boon Huat Bay

    BMC Cancer 2017 17:201

    Published on: 16 March 2017

  15. Study protocol

    iCanADAPT Early protocol: randomised controlled trial (RCT) of clinician supervised transdiagnostic internet-delivered cognitive behaviour therapy (iCBT) for depression and/or anxiety in early stage cancer survivors -vs- treatment as usual

    This RCT with two parallel arms will evaluate the efficacy of an internet-delivered transdiagnostic cognitive behavioural therapy (iCBT) intervention for the treatment of clinical depression and/or anxiety in ...

    M. J. Murphy, J. M. Newby, P. Butow, L. Kirsten, K. Allison, S. Loughnan, M. A. Price, J. Shaw, H. Shepherd, J. Smith and G. Andrews

    BMC Cancer 2017 17:193

    Published on: 15 March 2017

  16. Research article

    Methylene blue photodynamic therapy induces selective and massive cell death in human breast cancer cells

    Breast cancer is the main cause of mortality among women. The disease presents high recurrence mainly due to incomplete efficacy of primary treatment in killing all cancer cells. Photodynamic therapy (PDT), an...

    Ancély F. dos Santos, Letícia F. Terra, Rosangela A. M. Wailemann, Talita C. Oliveira, Vinícius de Morais Gomes, Marcela Franco Mineiro, Flávia Carla Meotti, Alexandre Bruni-Cardoso, Maurício S. Baptista and Leticia Labriola

    BMC Cancer 2017 17:194

    Published on: 15 March 2017

Previous Page Page 1 of 299 Next Page